ArticleBriefings in bioinformatics2026
CrisprPr: a hybrid-driven framework for CRISPR/Cas9 off-target prediction with analysis of prior-information updates.
Article in Briefings in bioinformatics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
CRISPR/Cas9 specificity is critically affected by off-target effects. However, the complex patterns of mismatches and their combinations at off-target sites remain difficult to capture, and existing approaches show limited capacity to identify informative features. Here, we present CrisprPr, a hybrid-driven off-target prediction framework that integrates both prior information and data-driven modeling to improve the characterization of off-target activity. CrisprPr employs a synchronous updating strategy that jointly optimizes prior-knowledge and deep-learning modules, together with multi-source integration, to deliver accurate and stable off-target predictions. Evaluations on independent test sets indicate that CrisprPr achieves competitive predictive performance and generalization compared with existing deep learning methods, with statistically significant improvements observed on several datasets. Beyond predictive performance, its analysis module examines the patterns of prior embedding-space updates to reveal distinctive target-site features supported by literature evidence. Overall, CrisprPr proposes a novel framework that demonstrates competitive predictive performance while offering new insights into the characteristics of off-target effects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.